Clinical trials / Cocaine and methamphetamine
Recruiting psychedelic and ketamine trials for cocaine and methamphetamine use
3 trials registered on ClinicalTrials.gov were recruiting on 13 Nov 2026, 2 of them at sites in the United States (2 states). By substance: Psilocybin 2, Ketamine / esketamine 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 13 Nov 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Trials with US sites
Early phase 1PsilocybinNCT06899594
Psilocybin for Methamphetamine Addiction
- Conditions:
- Methamphetamine Use Disorder
- Sponsor:
- Kevin Murnane
- Who:
- ages 25 Years to 65 Years, 20 participants planned
- LSU Health Shreveport, Shreveport, Louisiana
Phase 2PsilocybinNCT07756736
Psilocybin Therapy for Methamphetamine Use Disorder and HIV (PRISM)
- Conditions:
- Methamphetamine Use Disorder; Human Immunodeficiency Virus (HIV)
- Sponsor:
- Nicky Mehtani, MD, MPH
- Who:
- ages 25 Years to 64 Years, 30 participants planned
- UCSF at Zuckerberg San Francisco General Hospital, San Francisco, California
Trials outside the United States
Phase 2Ketamine / esketamineNCT06125054
Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction (Co-Boost)
- Conditions:
- Cocaine Use Disorder; Cocaine Dependence
- Sponsor:
- Dr. med. Marcus Herdener
- Who:
- ages 18 Years to 55 Years, 120 participants planned
- Where:
- Switzerland